PORTFOLIO COMPANION DIAGNOSTICS ENABLING TECHNOLOGIES RESOURCES OUR CULTURE About Contact Careers Search HomePartnered R&D Partnered R&D Asuragen’s R&D team and our CAP-accredited CLIA laboratory are both used to support our internal and partnered product development. Our wide menu of capabilities coupled with our flexible partnering approach means you can utilize us as a single provider to partner across your research, development and diagnostic needs. Our wide menu of offerings range from RNA-Seq to targeted, high homology sequencing. This broad technology reach ensures we can tailor our test offering to best match your project and clinical needs across Genetics, Oncology and the broader Custom & Companion Diagnostic space. Routine Applications CAP-Accredited CLIA Lab CTA Testing Site Routine Applications Custom & Companion Diagnostics We leverage our R&D team, established CAP-accredited CLIA laboratory capabilities and extensive experience with molecular technologies to support your biomarker discovery and detection needs. Our bioinformatics-driven approach coupled with our significant experience with complex, hard-to-amplify targets and samples, enables us to rapidly confirm and validate clinically-relevant mutations and accelerate your research and development cycles. Asuragen offers a broad range of technologies with high sensitivity and accuracy supported by an advanced bioinformatics capability, including: Genetics Leveraging proprietary enabling technologies, we have built a menu of tests to interrogate clinically-relevant GC-rich and high homology sequences. In order to improve the understanding of genetic disorders, we have developed a range of tests for fragile X syndrome and Amyotrophic Lateral Sclerosis (ALS). Fragile X: FMR1 Analyses PCR/CE FMR1 for detection of CGG repeats mPCR to examine methylation status Xpansion Interpreter® for interrogation of AGG interruptions Learn more about Xpansion Interpreter ALS: PCR/CE C9orf72 Oncology Leveraging our broad molecular biology and oncology capabilities, we have developed a menu of clinically-relevant tests to support needs ranging from development to diagnostics. qPCR BCR-ABL Detection of extremely low levels of the t(9:22) Philadelphia chromosome and reporting directly onto the International Scale (IS) NGS Pan Cancer Accurate detection of somatic mutations across many clinically relevant oncogenes from difficult to use FFPE tissues with limiting DNA quantities NGS ERBB2 Investigate the impact gene mutations and amplifications have on efficacy of targeted therapies directed at the HER family of receptors NGS TP53 Determination of the effect of activating or inactivating somatic or germline mutations on cell cycle, apoptosis, or therapeutic efficacy CAP-Accredited CLIA Lab Asuragen’s laboratory is licensed/certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA 88) and the requirements of the state of Texas licensure program. The Asuragen laboratory is accredited by the College of American Pathologists (CAP). CTA Testing Site Assays are analytically validated in Asuragen’s CAP-accredited CLIA lab with quality assurance oversight compliant with 42CFR493 regulations and the guidelines established by the 2009 AMP Clinical Practice Committee as well as the 2012 CAP molecular checklist. Companion Diagnostics Commercialization Product Approval Development Discovery Partnered R&D QUICK LINKS Licenses & Accreditations 2150 Woodward St., Suite 100 Austin, TX 78744 USA PORTFOLIO COMPANION DIAGNOSTICS ENABLING TECHNOLOGIES RESOURCES COMMUNITY About Contact Careers © Copyright 2021 ASURAGEN, INC. An Equal Opportunity Employer. All Rights Reserved. Privacy Policy Website Terms of Use Financial Conflict of Interest Policy